Third quarter 2026 earnings call, November 4, 2026

Niagen Bioscience reported a third quarter that management itself frames as a transition: a core consumer business under pricing pressure from NMN and low-cost NAD boosters, an ingredients business facing similar competition, and a growing list of bets on cost reduction, skin care, clinic-based NAD delivery and a rare disease drug candidate. Net sales were $27.2 million. Tru Niagen contributed $23.3 million, down 10%, or $2.7 million, year over year. The company posted a net loss of $1.2 million, or $0.01 per diluted share, against net income of $0.06 per share a year earlier. Adjusted EBITDA was positive at $455,000, and operating cash flow was about $2.6 million. Management is explicit that 2026 is an investment year and that growth is expected to arrive in 2027.

A Cheaper NR Salt Form Is the Most Consequential Strategic Change

The most important new disclosure concerns cost of goods. Niagen acquired patents in late 2025 covering NR salt forms beyond NR chloride, and it is now preparing one of them for commercialization. CEO Rob Fried identified it on the call as malate. The company says it can be manufactured at significantly lower cost, which would let Niagen cut prices to ingredient customers, who it concedes find price a hurdle. Ingredient qualification is being completed, with commercialization expected in early 2027.

Fried said the existing research carries over: "The salt simply dissolves away once it's exposed to liquid." Malate will go first to ingredient partners, and eventually into the Tru Niagen consumer line in territories where regulatory approval allows, though "not so much in the short term." Fried guided that it "will reduce our cost of goods in some way in 2027 and in a significant way after that." No dollar figures or margin targets were provided. Gross margin was 62.9% against 64.5% a year ago, and the new salt is the clearest lever management has to defend it while it responds to NMN competition.

Core Business: Website Strength, Distribution Weakness

The Tru Niagen decline was concentrated outside the company's own website. Direct-to-consumer sales rose 13% year over year, or about 17% after adjusting for Prime Day timing, which fell in the third quarter of 2025 and the second quarter of 2026. Management cited that as evidence that demand for the higher-priced, more heavily researched product persists despite cheaper entrants. The distribution channel was weaker, reflecting the timing of Watsons orders and the absence of a sizable order from a large health care practitioner distribution partner in the prior-year quarter. CFO Ozan Pamir said current order visibility supports a return of the Watsons contribution to prior-year levels.

The ingredients business generated $3.8 million, split between $3.4 million of food-grade and $425,000 of pharmaceutical-grade Niagen. Management attributed the weakness to order timing and size, but Fried also acknowledged that one large customer is experiencing continued competition from NMN and other products marketed as NAD supplements. New, mostly international ingredient partners, including contract manufacturers, were added in the quarter and are starting small. Niagen has sued the FDA over its NMN decision, and management said all commercially available NMN products infringe its patents. A favorable federal court ruling last week reversed the attorney's fee award against Niagen in its Elysium litigation, though management described it only as a step toward closing the matter. Legal costs remain a drag.

Retail distribution is widening. Tru Niagen is now on Walmart.com, in nearly 300 GNC locations and in Sam's Club across 44 states. Pamir said Sam's carries one SKU, with "early signs of strength," and the company hopes for Costco later. New Tru Niagen healthy aging supplements are planned for 2027.

Margins Squeezed by Brand Spending and Litigation

Selling and marketing expense was $8.7 million, nearly flat in dollars but 32% of sales versus 25.8% a year ago, driven by new product launches, China cross-border and brand awareness. General and administrative expense rose about $1.1 million to $8.2 million on litigation costs. R&D was flat at $1.8 million. Pamir said legal costs should ease from this level once cases resolve, but also guided to higher selling and marketing, R&D and G&A spending into the fourth quarter. The "Don't Get Old, Age Better" campaign with surfer Kelly Slater launched in October, so related creative costs land in Q4. Management expects fourth quarter revenue to improve sequentially, but with spending rising, the near-term profit picture looks challenging.

The balance sheet gives room to absorb this. Cash was $69.5 million with no debt, working capital was $83.3 million, and $14.6 million remains on a $20 million buyback authorization.

NB4168: Rare Disease Optionality, With Financing Likely

Management leaned heavily on NB4168, its proprietary NAD-boosting drug candidate. IND-enabling studies with Evotec have begun, and preclinical models show neuroprotective and lifespan-promoting effects. Fried said the company expects to complete IND-enabling work in 2027, "hopefully, even the first half," with first-in-human studies to follow, subject to regulatory clearance. A basket-style Phase II across orphan indications is under consideration, building on external research in ataxia-telangiectasia, Werner syndrome, Cockayne syndrome, Friedreich's ataxia and citrin deficiency.

Fried described the molecule as "clearly biosuperior" to NR chloride, with much greater bioavailability, and argued the science is "relatively derisked" given the two published Phase II studies of Niagen in ataxia-telangiectasia. He also said a joint venture or separate financing for the pharmaceutical unit is "very possible" in 2027: "We know we have a tiger by the tail." Pamir countered that current studies are easily affordable from the balance sheet.

Management pointed to two priority review voucher sales at $203 million and $210 million and Shionogi's $2 billion upfront acquisition of IntraBio, which won approval of Aqneursa for A-T. Investors should treat these as precedent rather than forecast. NB4168 has not entered humans, and as Fried noted, the opportunity "would depend on the available evidence and agreement with the FDA on an appropriate study design."

Niagen Plus and the Mass General Brigham Trial

Niagen Plus is gaining traction in clinics. Restore Hyper Wellness has made Niagen a flagship offering across more than 200 locations. Fried said its pricing was possible because of competitive dynamics Niagen introduced through an expanded compounding pharmacy network. On October 22 the company launched a ready-to-inject liquid at-home kit, replacing the powder vial that required reconstitution and refrigeration. A pen format is in development and may take about a year. Other large telehealth partners have expressed interest in the kit. No revenue figures for Niagen Plus were disclosed.

The company also agreed to a large prevention trial with Mass General Brigham, led by Dr. Howard Sesso of the COSMOS trial. Planning currently calls for about 5,000 participants over 3 years, with Fried expecting both to grow. Outcomes under consideration include biological clocks, intrinsic capacity, frailty indices and disease incidence in cognitive, cardiovascular and metabolic domains. Niagen is in talks with other large entities that might join and add a second ingredient. The company has not disclosed its financial commitment, and a multiyear prevention readout is a long-dated catalyst.

Skin Care and China Offer Upside, With Timing Uncertain

A topical product with a large global skin care partner is expected in early 2027, with a new Niagen-branded skin care product in the first half. NanoCloud is now permanent, and Fried said early sales have been "very, very strong," though no figures were given. He cited an independent Estee Lauder division study comparing NR favorably to niacinamide, and company data showing topical Niagen raises NAD levels in skin cells and reaches the blood. Fried hopes owned brands will eventually exceed ingredient sales.

China cross-border sales were not broken out, but Pamir said they are expected to be "more than 2 to 3x compared to last year." The larger prize is Blue Hat approval for in-country sales, which requires a manufacturing change and probably a toxicity study. Fried said that could be a year away and that Mainland China could be "probably bigger than the U.S. market for Tru Niagen." That remains a hypothesis until the approval is in hand.